The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile
Open accessPublished version of a preprint
Abstract
Background: Weight loss therapy is becoming more and more important, and two classes of molecules, namely amylin receptor and GLP-1 receptor agonists, have shown promise in this regard. Interestingly, these molecules have several overlapping pharmacological effects, such as suppression of gastric emptying, reduction of glucagon secretion and weight loss in common; however, they also have distinct effects on prandial insulin secretion. Hence, a combination of these two mechanisms is of significant interest. Methods: In this study, we investigated the add-on potential of the dual amylin and calcitonin receptor agonist (DACRA) KBP-089 in combination with the GLP-1 receptor agonist liraglutide as obesity treatment in high-fat diet (HFD) fed rats. Results: Increasing doses of KBP-089 and liraglutide alone and in combination were studied with respect to their effects on body weight, food intake and glucose metabolism during a 9-week intervention study conducted in HFD rats. Further, the gastric emptying rate during an oral glucose tolerance was assessed. Treatment with KBP-089 and liraglutide dose-dependently lowered body weight 15% (at 2.5 μg/kg/day) and 7% (at 400 μg/kg/day) in HFD rats, respectively, while the combination resulted in a 21% body weight reduction, which was mirrored by reduction in fat depot sizes. Gastric emptying and glucose metabolism were improved, primarily by KBP-089, although liraglutide led to a reduction in fasting plasma glucagon. Conclusion: DACRAs complement GLP-1 on food intake, body weight, and glucose tolerance indicating the potential for an add-on therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, studies in high fat diet fed rats have shown that the combination of the GLP-1 RA liraglutide with a dual amylin and calcitonin receptor agonist (DACRA) results not only in more WL, but also in improvement in glycemia compared to liraglutide monotherapy and DACRA monotherapy, demonstrating the potential for combining GLP-1 RA with amylin RA in T2D management [66].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855
Haslam, D. W., & James, W. P. T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67483-1 · Cited by 3,757
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757
Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations
Milić, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i28.9330 · Cited by 583 · cited 1×
“(NAFLD), non-alcoholic steatohepatitis (NASH), and other obesity related morbidities [7, 32].”
Backgroundvan Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537
Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.-P., Verhoeven, R., Bugánová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 468
Bariatric Surgery: Risks and Rewards
Pories, W. J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1641 · Cited by 405
Ratner, R. E., Dickey, R., Fineman, M., Maggs, D. G., Shen, L., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01319.x · Cited by 307
Cited by
A survey of the mouse hindbrain in the fed and fasted states using single-nucleus RNA sequencing
Dowsett, G. K. C., Lam, B. Y. H., Tadross, J. A., Cimino, I., Rimmington, D., Coll, A. P., Polex-Wolf, J., Knudsen, L. B., Pyke, C., & Yeo, G. S. H. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101240 · Cited by 98
Mediators of Amylin Action in Metabolic Control
Boyle, C. N., Zheng, Y., & Lutz, T. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082207 · Cited by 77
Peptides in the regulation of glucagon secretion
Andersen, D. B., & Holst, J. J. (2021) · Peptides · doi:10.1016/j.peptides.2021.170683 · Cited by 53
Gasbjerg, L. S., ROSENKILDE, M. M., Meier, J. J., Holst, J. J., & Knop, F. K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15216 · Cited by 45
“…should be challenged by comparison with other combination approaches (e.g. combinations of GLP-1 and GIP analogues, or GLP-1 and amylin analogues, 132 or GLP-1 analogues and GIP receptor antagonists 58,121,122 ), where the dose ratios could be easily adjusted according to personalized needs,…”
BackgroundLarsen, A. T., Mohamed, K. E., Sonne, N., BREDTOFT, E.-M., Andersen, F., Karsdal, M. A., & Henriksen, K. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113842 · Cited by 43
Self-citation
Metadata
- Authors
- Larsen, A. T., Gydesen, S., Sonne, N., Karsdal, M. A., & Henriksen, K.
- Affiliations
- Nordic Bioscience (Denmark) (DK)
- Corresponding author
- Henriksen, Kim
- Venue
- BMC Endocrine Disorders
- Published
- 2021-01-07
- Volume
- 21
- Issue
- 1
- Pages
- 10-10
- ISSN
- 1472-6823 (ISSN-L)
- PMC
- PMC7791885
- OpenAlex
- W3119986206
- Cited by
- 33
- References
- 45
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 8 · 2023: 6 · 2022: 3 · 2021: 4
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- BMC Endocrine Disorders (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Den Danske Forskningsfond (N/A)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- liraglutide, amylin receptor agonist, GLP-1 receptor agonists, obesity treatment, weight loss, high-fat diet, gastric emptying, glucose tolerance, dietary intake, glucagon, insulin secretion, combination therapy
- MeSH terms
- Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Blood Glucose, Drug Therapy, Combination, Glucagon-Like Peptides, Glucose Tolerance Test, Hypoglycemic Agents, Male, Obesity, Weight Loss, Rats, Sprague-Dawley, Receptors, Calcitonin, Rats, Metabolome, Receptors, Islet Amyloid Polypeptide, Diet, High-Fat, Amylin Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile. https://app.cochat.ai/papers/10.1186/s12902-020-00678-2
- The paper
- Larsen, A. T., Gydesen, S., Sonne, N., Karsdal, M. A., & Henriksen, K. (2021). The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-020-00678-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.